

Global mucormycosis market expected to reach \$616.1 M by 2028

08 June 2021 | News

The emergence of the COVID-19 pandemic along with the increasing cases of blood cancers and diabetes will be the main factors for the growth of the global market during the forecast period



The global mucormycosis market size is expected to reach \$616.1 million by 2028 according to a new study by Polaris Market Research. The report 'Mucormycosis Market Share, Size, Trends, Industry Analysis Report; By Diagnosis (Computed Tomography, MRI, Tissue Biopsy); By Treatment (Surgery, Antifungal Drugs, Amphotericin B Therapy, Others); By End-Use; By Region; Segment Forecast, 2021 – 2028' gives a detailed insight into current market dynamics and provides analysis on future market growth.

The emergence of the COVID-19 pandemic along with the increasing cases of blood cancers and diabetes will be the main factors for the growth of the global market during the forecast period. Organ and bone marrow transplantation along with increasing immune-competent patients due to the conditions like HIV will also boost the growth of the global market.

Mucormycosis cases are increased in the COVID-19 patients who have undergone treatment. Steroid drugs are typically used to manage the disease condition in these patients and even though the drugs are effective in treating corona it will lead to weak immune system and blood sugar level and the patients who taken steroid medication are prone to developing mucormycosis.

In India, there is an enormous increase in fungal infection, and in few hospitals in urban areas, five to ten people are coming for mucormycosis treatment. Before the pandemic, mucormycosis was very rare and the emergence of COVID-19 is expected to give a major boost to the growth of the global market.

Every year nearly 1.8 million haematological cancers are diagnosed across the globe and bone marrow transplantation is a treatment procedure to treat these conditions. The improved technology has resulted in the increased organ transplantation in the market. In the US market alone, nearly, 37,000 organ transplant procedures were conducted, in 2018. Most of the patients who underwent transplant take immunosuppressive drugs which will put them at the risk of developing mucormycosis.

Mucormycosis is a deadly fungal disease caused by species such as Rhizopus, Mucor, Saksenaea, Apophysomyces, Lichtheimia, Cunninghamella, Rhizomucor, and others. The mortality rate of mucormycosis ranges from 17 to 66 per cent in patients and the patients who overcome mucormycosis will suffer from blindness and organ dysfunction.

Computed tomography (CT), Magnetic resonance imaging (MRI), and tissue biopsy are mainly used in the diagnosis of fungal infection in the market. Amphotericin B therapy, surgery, and antifungal drugs are the main treatment methods to cure mucormycosis. Many new drugs in the market are approved to treat mucormycosis due to the increasing number of fungal

infections. For instance, in March 2021, Bharat Serums and Vaccines received Indian regulatory approval (DGCI) for the use of Liposomal Amphotericin B or LAmB for the treatment of mucormycosis.

Market participants such as Biocon, Abbott Laboratories, Cadila Pharmaceuticals, F Hoffman La Roche, Novartis, Merck Sharp and Dohme, Bristol Myers Squibb, Mylan Labs, Bayer, Sanofi, Lonza Group, Johnson & Johnson, Gilead Sciences, and Pfizer are some of the key players operating in the global market.